NIAGEN BIOSCIENCE, INC. Gain (Loss) Related to Litigation Settlement
NIAGEN BIOSCIENCE, INC. (NAGE) reported Gain (Loss) Related to Litigation Settlement of $2.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-04.
Financial Statements › Income Statement › Other Income
us-gaap:GainLossRelatedToLitigationSettlement · last filed 2026-03-04
- NIAGEN BIOSCIENCE, INC. gain (loss) related to litigation settlement for the quarter ending 2017-09-30 was -$746.00K.
- NIAGEN BIOSCIENCE, INC. gain (loss) related to litigation settlement for the quarter ending 2017-07-01 was -$746.00K.
- NIAGEN BIOSCIENCE, INC. gain (loss) related to litigation settlement for fiscal 2025 was $2.00M.
- NIAGEN BIOSCIENCE, INC. gain (loss) related to litigation settlement for fiscal 2018 was -$746.00K.
- NIAGEN BIOSCIENCE, INC. gain (loss) related to litigation settlement for fiscal 2017 was -$746.00K.
| Period end | Gain (Loss) Related to Litigation Settlement 3 month | Gain (Loss) Related to Litigation Settlement 6 month | Gain (Loss) Related to Litigation Settlement 12 month |
|---|---|---|---|
| 2025-12-31 | $2.00M 10-K · filed 2026-03-04 | ||
| 2018-12-31 | -$746.00K 10-K · filed 2019-03-07 | ||
| 2017-12-30 | -$746.00K 10-K · filed 2018-03-15 | ||
| 2017-09-30 | -$746.00K 10-Q · filed 2017-11-09 | -$1.49M derived: sum of 2 quarters · filed 2017-11-09 | |
| 2017-07-01 | -$746.00K 10-Q · filed 2017-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| USANA HEALTH SCIENCES INC (USNA) | United States | $0.264B | -17.90 |
| FITLIFE BRANDS, INC. (FTLF) | United States | $0.087B | 16.59 |
| Canopy Growth Corp (CGC) | $0.395B | ||
| MANNATECH INC (MTEX) | United States | $0.014B | |
| NATURAL ALTERNATIVES INTERNATIONAL INC (NAII) | United States | $0.011B | -1.16 |
| Synergy CHC Corp. (SNYR) | United States | $0.001B | |
| Functional Brands Inc. (MEHA) | United States | $0.001B | |
| Tilray Brands, Inc. (TLRY) | United States | $0.554B | -5.97 |
| Cronos Group Inc. (CRON) | $1.223B | ||
| Definium Therapeutics, Inc. (DFTX) | United States | $4.931B | -17.87 |